A 65-year-old woman with a history of myocardial infarction 2 years ago and recurrent angina despite atorvastatin 80 mg daily presents with LDL cholesterol of 95 mg/dL and triglycerides of 280 mg/dL. She has no contraindications to additional therapy. Which agent should be added to further reduce her atherosclerotic burden and cardiovascular risk?

Question

Accepted Answer

C. Ezetimibe. ## Rationale for Ezetimibe as Second-Line Agent

**Key Point:** When statin monotherapy fails to achieve LDL goal (target <70 mg/dL in secondary prevention), ezetimibe is the preferred second-line agent. It has proven cardiovascular benefit when added to statins and is cost-effective, well-tolerated, and guideline-recommended.

### Clinical Context: This Patient's Lipid Profile
- **LDL 95 mg/dL** on atorvastatin 80 mg = above secondary prevention goal (<70 mg/dL)
- **Triglycerides 280 mg/dL** = elevated but not the primary driver of ASCVD in secondary prevention
- **Indication:** Requires intensification of LDL-lowering therapy

### Mechanism of Ezetimibe
Ezetimibe inhibits Niemann-Pick C1-like 1 (NPC1L1) protein in the small intestine, blocking cholesterol absorption:
1. Reduces intestinal cholesterol uptake by ~50%
2. Increases hepatic LDL receptor expression (synergistic with statin)
3. Lowers LDL by an additional 15–20% when added to statin
4. Well-tolerated with minimal drug interactions

### Evidence for Ezetimibe + Statin
**High-Yield:** The IMPROVE-IT trial (2015) demonstrated that ezetimibe added to simvastatin in post-ACS patients reduced cardiovascular events by 6% compared to statin alone, with a 24% relative risk reduction in the composite endpoint. This is the landmark trial supporting ezetimibe in secondary prevention.

### Comparison of Second-Line Agents for LDL Reduction

| Agent | LDL Reduction | Indication | Evidence | Tolerability |
|-------|---------------|-----------|----------|-------------|
| **Ezetimibe** | 15–20% | Statin inadequacy | IMPROVE-IT: proven CV benefit | Excellent |
| **Fenofibrate** | 5–15% | Hypertriglyceridemia | No CV benefit in statin-treated | GI upset, myopathy risk |
| **Niacin** | 15–25% | Mixed dyslipidemia | AIM-HIGH, HPS2-THRIVE: no added benefit | Flushing, GI, hyperglycemia |
| **Inclisiran** | 50–60% | Statin-intolerant or very high-risk | ORION trials: CV outcomes pending | Expensive, rare; not yet standard |

**Clinical Pearl:** In this patient with recurrent angina despite statin therapy, the priority is LDL reduction to <70 mg/dL. Ezetimibe is the evidence-based next step. Triglycerides at 280 mg/dL are elevated but do not warrant fibrate monotherapy; if triglycerides remain high after ezetimibe, icosapent ethyl (high-dose EPA) may be considered if LDL is at goal.

**Mnemonic:** **EZETIMIBE** = **E**xternal **Z**one **E**nteric **T**ransporter **I**nhibitor **M**akes **I**ncremental **B**enefit **E**vident (in secondary prevention).

## Why Ezetimibe Is Preferred Over Alternatives
- Proven cardiovascular benefit in IMPROVE-IT (post-ACS population)
- Additive LDL reduction without statin dose escalation
- Excellent safety profile; no myopathy risk
- Guideline-recommended as second-line by ACC/AHA and ESC
- Cost-effective and widely available

Answer

A. Inclisiran

Answer

B. Fenofibrate

Answer

D. Niacin

Explanation

Rationale for Ezetimibe as Second-Line Agent

Clinical Context: This Patient's Lipid Profile

Mechanism of Ezetimibe

Evidence for Ezetimibe + Statin

Comparison of Second-Line Agents for LDL Reduction

Why Ezetimibe Is Preferred Over Alternatives

Practice similar questions

Join our NEET PG community

Agent	LDL Reduction	Indication	Evidence	Tolerability
Ezetimibe	15–20%	Statin inadequacy	IMPROVE-IT: proven CV benefit	Excellent
Fenofibrate	5–15%	Hypertriglyceridemia	No CV benefit in statin-treated	GI upset, myopathy risk
Niacin	15–25%	Mixed dyslipidemia	AIM-HIGH, HPS2-THRIVE: no added benefit	Flushing, GI, hyperglycemia
Inclisiran	50–60%	Statin-intolerant or very high-risk	ORION trials: CV outcomes pending	Expensive, rare; not yet standard